Literature DB >> 12486261

Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses.

M-L Sumelahti1, P J Tienari, M Hakama, J Wikström.   

Abstract

OBJECTIVE: To compare the secular trends and geographical differences in the incidence of relapsing-remitting (RRMS) and primary progressive multiple sclerosis (PPMS) in Finland, and to draw inferences about aetiological differences between the two forms of the disease.
METHODS: New multiple sclerosis cases in southern Uusimaa and the western districts Vaasa and Seinäjoki of Finland in 1979-1993 were verified from hospital records and classified into RRMS and PPMS. Patients met the Poser criteria for definite multiple sclerosis or otherwise satisfied the criteria for PPMS. Disease course was categorised by the same neurologist. Crude and age adjusted incidence in 1979-1993 was estimated.
RESULTS: During 1979-1993 the age adjusted incidence was 5.1 per 100 000 person-years in Uusimaa, 5.2 in Vaasa, and 11.6 in Seinäjoki. The rates in Uusimaa remained stable, while a decrease occurred in Vaasa and an increase in Seinäjoki. Between 1979-86 and 1987-93 the incidence of PPMS increased in Seinäjoki from 2.6 to 3.7 per 10(5) and decreased in Vaasa from 1.9 to 0.2 per 10(5); the trends were similar for RRMS.
CONCLUSIONS: There are significant differences in secular trends for multiple sclerosis incidence in Finland by geographical area, but these are similar for PPMS and RRMS. The recent changes point to locally acting environmental factors. The parallel incidence trends for RRMS and PPMS suggest similar environmental triggers for the two clinical presentations of multiple sclerosis.

Entities:  

Mesh:

Year:  2003        PMID: 12486261      PMCID: PMC1738192          DOI: 10.1136/jnnp.74.1.25

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  Studies on the clustering of multiple sclerosis in Finland II: microepidemiology in one high-risk county with special reference to familial cases.

Authors:  J Wikström
Journal:  Acta Neurol Scand       Date:  1975-03       Impact factor: 3.209

2.  Geography in multiple sclerosis.

Authors:  J F Kurtzke
Journal:  J Neurol       Date:  1977-04-28       Impact factor: 4.849

3.  Western Norway, a high-risk area for multiple sclerosis: a prevalence/incidence study in the county of Hordaland.

Authors:  J P Larsen; J A Aarli; H Nyland; T Riise
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

4.  The epidemiology of multiple sclerosis in Finland: increase of prevalence and stability of foci in high-risk areas.

Authors:  E Kinnunen; J Wikström; J Porras; J Palo
Journal:  Acta Neurol Scand       Date:  1983-05       Impact factor: 3.209

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Genetic markers in Finland.

Authors:  H R Nevanlinna
Journal:  Haematologia (Budap)       Date:  1980

7.  Clinical and laboratory features of primary progressive and secondary progressive MS.

Authors:  K Bashir; J N Whitaker
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

8.  Multiple sclerosis after age 50.

Authors:  J Noseworthy; D Paty; T Wonnacott; T Feasby; G Ebers
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

9.  Histocompatibility antigens in familial multiple sclerosis in a high-risk area of the disease.

Authors:  E Kinnunen; S Koskimies; A Lagerstedt; J Wikström
Journal:  J Neurol Sci       Date:  1984-08       Impact factor: 3.181

10.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

View more
  8 in total

1.  Segmental duplications flank the multiple sclerosis locus on chromosome 17q.

Authors:  Daniel C Chen; Janna Saarela; Royden A Clark; Timo Miettinen; Anthony Chi; Evan E Eichler; Leena Peltonen; Aarno Palotie
Journal:  Genome Res       Date:  2004-07-15       Impact factor: 9.043

2.  Multiple sclerosis in the province of Ferrara : evidence for an increasing trend.

Authors:  E Granieri; N-T Economou; R De Gennaro; M R Tola; L Caniatti; V Govoni; E Fainardi; I Casetta
Journal:  J Neurol       Date:  2007-11-16       Impact factor: 4.849

3.  Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis.

Authors:  Shabnam Behrangrad; Amin Kordi Yoosefinejad
Journal:  Int J MS Care       Date:  2020-02-14

4.  Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring.

Authors:  Enrique Alcalde-Cabero; Javier Almazán-Isla; Antonio García-Merino; Joao de Sá; Jesús de Pedro-Cuesta
Journal:  BMC Neurol       Date:  2013-06-12       Impact factor: 2.474

5.  Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up.

Authors:  Marja-Liisa Sumelahti; Markus H A Holmberg; Annukka Murtonen; Heini Huhtala; Irina Elovaara
Journal:  Mult Scler Int       Date:  2014-11-09

6.  Multiple sclerosis in the far north--incidence and prevalence in Nordland County, Norway, 1970-2010.

Authors:  Espen Benjaminsen; Johnny Olavsen; Merethe Karlberg; Karl B Alstadhaug
Journal:  BMC Neurol       Date:  2014-12-04       Impact factor: 2.474

7.  A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015.

Authors:  Tanja Daltrozzo; Alexander Hapfelmeier; Ewan Donnachie; Antonius Schneider; Bernhard Hemmer
Journal:  Front Neurol       Date:  2018-10-30       Impact factor: 4.003

Review 8.  Environmental and genetic risk factors for MS: an integrated review.

Authors:  Emmanuelle Waubant; Robyn Lucas; Ellen Mowry; Jennifer Graves; Tomas Olsson; Lars Alfredsson; Annette Langer-Gould
Journal:  Ann Clin Transl Neurol       Date:  2019-08-07       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.